Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-055372

Allogene Therapeutics, Inc. · ALLO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Arie Belldegrun
Director · 10% Owner
Period of report
Oct 15, 2018
Accepted (ET)
Oct 17, 2018 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001737287

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockOct 15, 2018P35,000$18.00A35,000D
Common StockF1,F2Oct 15, 2018C142,248—A3,710,006ISee footnote
Common StockF1,F3Oct 15, 2018C5,989,352—A5,989,352ISee footnote
Common StockF1,F4Oct 15, 2018C1,497,336—A1,497,336ISee footnote
Common StockF5holding———488,250ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Convertible Preferred StockF2,F1—Oct 15, 2018C27,095D——Common Stock142,2480I
Series A Convertible Preferred StockF3,F1—Oct 15, 2018C1,140,829D——Common Stock5,989,3520I
Series A Convertible Preferred StockF4,F1—Oct 15, 2018C285,207D——Common Stock1,497,3360I

Explanation of responses